Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Regorafenib is an approved agent in patients with advanced hepatocellular carcinoma (HCC) who progressed on sorafenib, but little is known about its clinical outcomes in Child-Pugh B patients. We aimed to investigate the safety and effectiveness of regorafenib in Child-Pugh B HCC patients.
Methods: This multicentre retrospective study included 59 patients with Child-Pugh B HCC who received regorafenib. Comparative analyses were performed with an independent cohort of Child-Pugh class A patients from the same registry (n = 440).
Results: The median age was 58 years (range, 19-83). All patients had progression on prior sorafenib. Regorafenib was given as 2nd line, and 3rd-4th line systemic therapy in 37 (62.7%) and 22 (37.3%) patients respectively. Compared to Child-Pugh A cohort, grade 3-4 AEs were more common in the Child-Pugh B cohort (27.1% vs 14.1%, P = .017). The median progression-free survival (PFS) and overall survival (OS) were 1.8 and 4.6 months, respectively, and these were significantly poorer than the Child-Pugh A cohort (P = .008 and P < .001 respectively). Child-Pugh B patients with albumin-bilirubin (ALBI) grade 3 had a significantly higher frequency of increased bilirubin (P = .01 for any grade and P = .01 for grade 3-4) and showed significantly poorer OS (P = .021), compared to those with ALBI grade 1 or 2.
Conclusion: Regorafenib's poor clinical outcomes and increased frequency of severe adverse events lead us to discourage its use in the Child-Pugh B population. In particular, regorafenib should not be used in Child-Pugh B patients with ALBI grade 3.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.14573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cone Unit-Based Anatomical Liver Resection Guided by Preoperative Embolization and ICG Fluorescence: A Novel Surgical Strategy.
Ann Surg Oncol
September 2025
Carle Illinois College of Medicine University of Illinois Urbana-Champaign, 509 W University Ave, Urbana, IL, 61801, USA.
Background: The liver cone unit (Tokyo 2020 terminology) of the peripheral portal vein territory represents the smallest anatomical and functional unit of the liver. While this unit enables anatomical, subsegmental resection, particularly in patients with cirrhosis, the tumor-bearing cone unit can be challenging to identify intraoperatively. PATIENTS AND METHODS: A 58-year-old man with hepatitis C-related cirrhosis (Child-Pugh B) was diagnosed with a subcapsular hepatocellular carcinoma (HCC) in segment 8.
View Article and Find Full Text PDFReal-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.
Liver Int
October 2025
CHU Amiens Picardie, Service D'hépato-gastroentérologie, Amiens, France.
Background And Aims: Atezolizumab-Bevacizumab (AtezoBev) was the first immunotherapy approved for hepatocellular carcinoma (HCC) in France, with initial trials primarily involving patients with viral-related liver disease. This prospective study aimed to evaluate the efficacy of AtezoBev in a French HCC population predominantly affected by non-viral liver disease.
Methods: Data from 545 HCC patients treated with AtezoBev as first-line systemic therapy were collected from 32 French centres in the CHIEF cohort between July 2020 and January 2023.
Platelet aggregation as a thrombotic marker in cirrhotic patients with portal vein thrombosis.
Clin Exp Hepatol
June 2025
Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin EL-Kom, Menoufia, Egypt.
Aim Of The Study: Portal vein thrombosis (PVT) is frequently observed in liver cirrhosis patients and correlates with the severity of the underlying liver disease. Thrombocytopenia and thrombocytopathy are signs of liver cirrhosis. A disruption in platelet function may have an impact on the development of thrombosis, considering that platelets are essential in the formation of thrombosis.
View Article and Find Full Text PDFImpact of thrombocytopenia and coagulopathy on partial hepatectomy and Hassab's operation in patients with cirrhosis: a multicenter retrospective cohort study.
Ann Med
December 2025
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Background: Thrombocytopenia (TCP) and coagulation disorders are common complications for patients with liver cirrhosis. The impact of severe TCP [30 × 10/L < platelets (PLT) ≤ 50 × 10/L] and coagulation disorder on bleeding risk after Hassab's operation or partial hepatectomy (PH) for cirrhotic patients is unclear.
Method: Our study retrospectively enrolled 724 cirrhotic patients from July 2019 to August 2024, including 189 patients who underwent Hassab's operation and 535 patients with hepatocellular carcinoma who underwent PH without prophylactic platelet transfusions or thrombopoietin receptor agonists.
Efficacy of N-acetylcysteine dexamethasone in preventing postembolization syndrome post-transarterial chemoembolization in hepatocellular carcinoma: A randomized controlled trial.
World J Gastroenterol
August 2025
Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Dusit 10300, Bangkok, Thailand.
Background: Hepatocellular carcinoma (HCC) is a major health concern in Thailand, with most patients diagnosed at the intermediate stage. Transarterial chemoembolization (TACE) is the standard treatment; however, postembolization syndrome (PES) remains a common complication. Although both dexamethasone (DEXA) and N-acetylcysteine (NAC) have shown efficacy in reducing PES, no study has directly compared their effects.
View Article and Find Full Text PDF